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Abstract: A retrospective study was conducted to evaluate the outcome of treatment with 
alendronate (ALN) for 5 years in postmenopausal Japanese women with an increased risk of 
fractures. Forty postmenopausal Japanese women with osteoporosis or osteopenia and clinical 
risk factors for fractures (mean age: 75.4 years) were analyzed; 33 patients were treated with 
alendronate and 7 were treated with alfacalcidol (ALF, controls) in an outpatient clinic run by 
general practitioners. The metacarpal bone mineral density (BMD) measured using a computed 
X-ray densitometer, urinary levels of cross-linked N-terminal telopeptides of type I collagen 
(NTX), and serum levels of alkaline phosphatase (ALP) were monitored during the 5-year 
treatment period. The urinary NTX and serum ALP levels decreased significantly in the ALN 
group, compared with the ALF group. The metacarpal BMD was sustained in the ALN group 
but decreased significantly in the ALF group; the difference between these two groups was 
also significant. The present study evaluated the outcome of treatment with ALN for 5 years 
in postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors 
for fractures. ALN successfully suppressed bone turnover and sustained the metacarpal BMD 
over the 5-year period of treatment in postmenopausal Japanese women with an increased risk 
of fractures.
Keywords: alendronate, osteoporosis, osteopenia, risk factors for fractures, postmenopausal 
women
Background
Osteoporosis most commonly affects postmenopausal women, placing them at a 
significant risk for fractures. Alendronate (ALN) and alfacalcidol (ALF) are widely 
used for the treatment of postmenopausal osteoporosis in Japan. The fracture inter-
vention trial showed the antifracture efficacy of ALN for vertebral, nonvertebral, 
hip, and writs fractures in postmenopausal women with osteoporosis.1,2 A recent 
systematic review analyzing 11 randomized controlled trials (RCTs) representing 
12068 women confirms both clinically important and statistically significant reduc-
tions in vertebral, nonvertebral, hip, and wrist fractures for secondary prevention (gold 
level evidence).3 However, current global evidence suggests that ALF does not help 
to prevent vertebral, nonvertebral, and hip fractures in postmenopausal women with 
osteoporosis.4 In postmenopausal Japanese women with osteoporosis, some evidence 
suggests that ALF helps to prevent vertebral fractures.5 A head-to-head trial showed 
that ALN was more effective than ALF for preventing vertebral fractures.6,7 Thus, 
ALN is regarded as a first-line drug and ALF is regarded as a second-line drug for 
the treatment of osteoporosis in Japan.Therapeutics and Clinical Risk Management 2009:5 774
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The long-term efficacy of anti-fracture drugs needs to be 
established. Bone et al8 reported their experience using ALN 
to treat postmenopausal Western women with osteoporosis 
for a period of 10 years. Ten years of treatment with ALN 
produced an increase in the bone mineral density (BMD) of 
13.7% at the lumbar spine, 10.3% at the trochanter, 5.4% 
at the femoral neck, and 6.7% at the total proximal femur, 
compared with the baseline values. Safety data, including 
fractures and stature, did not suggest that prolonged treatment 
resulted in any loss of benefit. Thus, the therapeutic effects of 
alendronate were sustained, and the drug was well tolerated 
over a 10-year period. In Japan, although the anti-fracture 
efficacy of treatment with ALN for 3 years against vertebral 
fractures has been reported in postmenopausal women with 
osteoporosis,7 the outcome of longer-term (3 years) treat-
ment with ALN remains to be established.
Based on the Japanese guideline for the prevention and 
treatment of osteoporosis,9 patients with osteoporosis or 
osteopenia and clinical risk factors for fractures should be 
treated using anti-fracture drugs. The presently reported 
retrospective study was conducted by Japanese general prac-
titioners to evaluate the outcome of treatment with ALN for 
5 years in postmenopausal Japanese women with osteoporo-
sis or osteopenia and clinical risk factors for fractures. The 
primary endpoint was metacarpal BMD, and the secondary 
endpoints were biochemical markers.
Subjects and methods
subjects
Forty postmenopausal Japanese women (age range: 60 to 
93 years, mean age: 75.4 years at the beginning of treatment) 
who had been treated with ALN or ALF for over 5 years were 
recruited at the outpatient clinic of Yahata Clinic (Tokyo, 
Japan) during the 3-month period between February 1 and 
April 30, 2009. The inclusion criteria were postmenopausal 
women with osteoporosis or osteopenia and clinical risk 
factors for fractures at the start of treatment. The clinical 
risk factors for fractures included current smoking, maternal 
history of hip fractures, alcohol consumption 2 units daily, 
age 75 years, leanness (body mass index 18.5 kg/m2), and 
history of steroid use. The exclusion criteria were histories 
of reflux esophagitis, gastric or duodenal ulcer, gastrectomy, 
or bone diseases, including primary hyperparathyroidism, 
hyperthyroidism, Cushing syndrome, multiple myeloma, 
rheumatoid arthritis, and osteogenesis imperfecta.
All the patients had been diagnosed as having osteo-
porosis according to the Japanese diagnostic criteria.10,11 
Namely, patients with a BMD  70% of the young adult 
mean (YAM) or of 70% to 80% of the YAM along with a 
history of osteoporotic fractures were diagnosed as having 
osteoporosis. Patients with a BMD of 70% to 80% of the 
YAM and without any history of osteoporotic fracture were 
diagnosed as having osteopenia. A preliminary screening 
included a medical history, physical examination, plain 
X-rays of the thoracic and lumbar spine, metacarpal BMD 
measurement, and blood and urinary biochemical tests 
including serum calcium, phosphorus, and alkaline phospha-
tase (ALP) and urinary cross-linked N-terminal telopeptides 
of type I collagen (NTX).
Of the 40 patients, 33 had been treated with ALN (5 mg 
daily or 35 mg weekly) and 7 had been treated with ALF 
(1 µg daily, controls) for over 5 years. Basically, ALN treat-
ment was recommended to all patients, but those who refused 
it were treated with ALF, because ALN is a first line drug 
whereas ALF is a second line drug. The doses indicated in 
the parentheses above are the doses used in Japan for the 
treatment of postmenopausal women with osteoporosis and 
have been recognized as being safe and effective.5,12 Daily 
ALN and ALF treatment were available throughout the study 
period, but weekly ALN treatment only became available after 
October 2006. All the patients in the ALN group had been 
treated with daily ALN and then switched to weekly ALN 
just after October 2006. The effects of daily and weekly ALN 
treatments on BMD and bone turnover markers as well as 
the incidence of side effects were reported to be similar in 
postmenopausal Japanese women with osteoporosis.13 The 
subjects did not receive either elementary calcium or natural 
vitamin D supplementation.
The urinary levels of NTX were measured at 3 months 
after the start of treatment based on the results of our previ-
ous study.14 Urinary NTX measurement at 3 months after the 
start of ALN treatment is important and enough to monitor 
its effect in the treatment of osteoporosis.14 The serum levels 
of calcium, phosphorus, and ALP and the metacarpal BMD 
were measured every 6 months after the start of treatment. 
The outcomes of treatment with ALN or ALF for 5 years 
were compared.
Informed consent was obtained from each patient with 
regard to the use of their clinical data in the present report. 
The present study was approved by the Ethics Committee 
of Yahata Clinic.
Assessment of vertebral fractures
Plain lateral X-ray films of the thoracic and lumbar spine 
were obtained at baseline to detect evidence of morphomet-
ric vertebral fractures. According to the Japanese criteria, Therapeutics and Clinical Risk Management 2009:5 775
Outcome of 5-year alendronate treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
a vertebral fracture was defined according to the vertebral 
height on lateral X-ray films.10,11 Briefly, the vertebral height 
was measured at the anterior (A), central (C), and posterior 
(P) parts of the vertebral body, and the presence of a vertebral 
fracture was confirmed when (1) a reduction in the vertebral 
height of more than 20% (A, C, and P) compared with the 
height of the adjacent vertebrae was observed, (2) the C/A 
or C/P was less than 0.8, or (3) the A/P was less than 0.75. 
The assessment for vertebral fractures was performed at the 
T4–L4 level.
Measurement of metacarpal BMD
An anteroposterior view radiograph of bilateral hands and an 
aluminum step wedge (20 steps, 1 mm per step) was obtained 
for each subject and was used as a standard. The BMD of 
the middle portion of the second metacarpus on the left hand 
was measured using a computed X-ray densitometer (Teijin, 
Tokyo, Japan). The densitometer calculated the BMD based 
on the pattern expressed as graduations on the aluminum 
step wedge, and the BMD was expressed as the thickness of 
the aluminum equivalent (mmAl) showing a corresponding 
X-ray absorption. For these measurements, the coefficients 
of variation (CV , 100 × standard deviation (SD)/mean) for the 
intraobserver error (based on 10 consecutive measurements 
by 5 persons), the daily change error (based on measure-
ments performed on 10 consecutive days), and the X-ray 
picturing error (based on 10 exposures) were all within 
1.3% to 3.8%.
statistical analysis
Data were expressed as the mean ± SD in the tables and the 
mean ± 95% confidence interval (CI) in the figures. Compari-
sons of the baseline characteristics between the 2 groups were 
performed using an unpaired t-test. The significance of longi-
tudinal changes in the parameters in a group was determined 
using a one-way analysis of variance (ANOVA) with repeated 
measurements. Longitudinal changes in the parameters were 
compared between the two groups using a two-way ANOVA 
with repeated measurements. The percentage of women with 
fractures at baseline was compared between the two groups 
using the Fisher exact test. All statistical analyses were per-
formed using the Stat View-J5.0 program. A significance level 
of P  0.05 was used for all the comparisons.
Results
Characteristics of the study subjects 
at the start of treatment
Table 1 shows the baseline characteristics of the study 
subjects. In the ALN group (n = 33), 19 patients had osteo-
porosis and 14 had osteopenia and clinical risk factors for 
fractures (n = 4 for age 75 years; n = 3 for leanness, n = 2 
each for history of steroid use (just transient use), current 
smoking, and maternal history of hip fractures; n = 1 for 
alcohol consumption 2 units daily). In the ALF group 
(n = 7), on the other hand, 5 patients had osteoporosis and 
2 had osteopenia and clinical risk factors for fractures (n = 1 
each for age 75 years and leanness).
Table 1 Characteristics of study subjects
ALN group (n = 33) ALF group (n = 7) P values
Age (years) 75.5 ± 7.8 74.9 ± 9.5 ns
height (m) 1.49 ± 0.07 1.52 ± 0.06 ns
Body weight (kg) 49.3 ± 8.8 49.3 ± 8.3 ns
Body mass index (kg/m2) 22.2 ± 3.1 21.1 ± 2.3 ns
Metacarpal BMD (mmAl) 1.92 ± 0.21 1.86 ± 0.19 ns
%YAM of metacarpal BMD (%) 70.2 ± 7.6 67.7 ± 6.8 ns
serum calcium (mg/dL) 9.1 ± 0.3 9.0 ± 0.4 ns
serum phosphorus (mg/dL) 3.6 ± 0.5 3.8 ± 0.6 ns
serum ALP (IU/L) 262 ± 74 231 ± 69 ns
Urinary nTX (nmol BCe/mmol Cr) 67.5 ± 24.9 55.5 ± 12.3 ns
number (%) of women with prevalent 9 (27.3) 1 (14.3) ns
vertebral fractures
number (%) of women with history of 
nonvertebral fractures
3 (9.1) 1 (14.3) ns
Notes: Data are expressed as the mean ± sD. Data comparison between the 2 groups was performed using an unpaired t-test. The percentage of patients with fractures 
were compared using the Fisher exact test.
Abbreviations: ALn, alendronate; ALF, alfacalcidol; BMD, bone mineral density;   YAM, young adult mean; ALP, alkaline phosphatase; nTX, cross linked n-terminal telopeptides 
of type I collagen; BCE, bone collagen equivalent; Cr, creatinine; NS, not significant.Therapeutics and Clinical Risk Management 2009:5 776
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No significant differences in any of the baseline 
characteristics including anthropometry, metacarpal BMD, 
biochemical markers and the number of patients with preva-
lent vertebral fractures or a history of nonvertebral fractures 
were observed between the two groups. The mean levels 
of urinary NTX in both groups suggested high turnover 
osteoporosis (the normal range for Japanese women: 9.3 to 
54.3 nmol bone collagen equivalents [BCE]/mmol Cr).15
Changes in biochemical markers 
and metacarpal BMD
Figure 1 shows the changes in the biochemical markers. The 
urinary NTX levels were reduced to the normal range for 
Japanese women (9.3 to 54.3 nmol BCE/mmol Cr)11 after 
3 months of treatment, and the serum ALP levels remained 
within the normal range (135 to 310 IU/L) during the 5-year 
period in the ALN groups. However, the urinary NTX and 
serum ALP levels did not change significantly in the ALF 
group. The mean change rates of the urinary NTX levels 
after 3 months of treatment in the ALN and ALF groups 
were −43.6% and +13.3%, respectively. The respective 
change rates of the serum ALP levels after 5 years of 
treatment were −18.0% and +0.8%. The urinary NTX and 
serum ALP levels decreased significantly in the ALN group, 
compared with in the ALF group (Table 2). However, the 
changes in the serum calcium and phosphorus levels did not 
differ significantly between the two groups.
Figure 2 shows the changes in metacarpal BMD. Meta-
carpal BMD was sustained in the ALN group (+0.4% at 
5 years) but decreased significantly in the ALF group (−5.4% 
at 5 years); the difference between the 2 groups was also 
significant (Table 2).
Discussion
The results of RCTs to test the effects of short-term 
(1 to 3 years) treatment with ALN on BMD, bone turnover 
markers, and fracture incidence have been reported in 
postmenopausal Japanese women with osteoporosis.6,7,12,13 
ALN reduces bone turnover markers, increases lumbar and 
hip BMD, and prevents vertebral fractures. However, the 
outcome of long-term (3 years) treatment with ALN has 
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Figure 1 Changes in biochemical markers.
Notes: Data are expressed as the mean ± 95% confidence interval (CI). The results of statistical analyses are shown in Table 2.
Abbreviations: ALn, alendronate; ALF, alfacalcidol; ALP, alkaline phosphatase; nTX, cross linked n-terminal telopeptides of type I collagen.Therapeutics and Clinical Risk Management 2009:5 777
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retrospective study was to evaluate the outcome of treatment 
with ALN for 5 years in postmenopausal women with osteo-
porosis or osteopenia and clinical risk factors for fractures 
according to the clinical practices of Japanese general prac-
titioners. The present study confirmed that ALN successfully 
suppressed bone turnover and sustained the metacarpal BMD 
over a period of 5 years in postmenopausal Japanese women 
with an increased risk of fractures. However, because with-
drawn patients were not included among the subjects in the 
present study, the 5-year safety of ALN treatment, including 
its adverse effects, remains uncertain.
In the present study, postmenopausal Japanese women 
with osteopenia and clinical risk factors for fractures 
were included among the study subjects. According to the 
Japanese guidelines for the prevention and treatment of 
osteoporosis,9 not only patients with osteoporosis, but also 
those with osteopenia and clinical risk factors for fractures 
should be treated using anti-fracture drugs. Clinical risk 
factors for fractures included current smoking, a maternal 
history of hip fractures, and alcohol consumption 2 units 
daily.9 In addition, the following factors were also included: 
age 75 years, leanness, and history of steroid use; a previ-
ous report in Japanese subjects indicated that these factors 
were risk factors for fractures independent of the BMD.9 Siris 
et al16 reported that using a peripheral measurement device, 
82% of postmenopausal women with fractures had T scores 
better than −2.5 and that a strategy for reducing the overall 
fracture incidence would likely require lifestyle changes and 
a targeted effort to identify and develop treatment protocols 
for women with less severe low BMD values who nonetheless 
had an increased risk for future fractures. Thus, it may be 
reasonable to treat postmenopausal women with osteopenia 
and clinical risk factors for fractures.
In postmenopausal Japanese women with osteoporosis, 
studies have shown that ALN (5 mg daily or 35 mg weekly) 
decreases the urinary NTX (−45% at 3 months) and serum 
ALP (about −20% at 3 years) levels and increases the lumbar 
BMD (+9.2% at 3 years).7,13 Another study showed that treat-
ment with ALN for 1 year increased the lumbar BMD but 
only sustained the metacarpal BMD.17 In the present study, 
treatment with ALN sustained the metacarpal BMD for 
5 years after reducing the urinary levels of NTX (−43.6% at 
3 months) and the serum levels of ALP (–18.0% at 5 years). 
The urinary NTX levels were reduced to within the normal 
range for Japanese women after 3 months of treatment, 
while the serum ALP levels remained within the normal 
range throughout the 5-year period of the present study. 
We evaluated serum NTX (the normal range for Japanese 
women: 7.5 to 16.5 nmol BCE/L)15 after 5 years treatment 
as not described in the subjects and methods section. The 
serum levels of NTX (nmol BCE/L, mean ± SD) at 5 years 
were 10.2 ± 2.8 for the ALN group and 17.6 ± 19.4 for the 
ALF group with a significant difference between the 2 groups 
(P  0.0001 by an unpaired t-test), suggesting the sustained 
effect of ALN over the 5-year period of treatment.
Dual-energy X-ray absorptiometry (DXA) is used to 
measure lumbar, femoral neck and forearm BMD, while 
computed X-ray densitometry can be used to measure meta-
carpal BMD. DXA-based BMD measurements at the lumbar 
spine and femoral neck are useful for predicting the risk of 
osteoporotic fractures in Japan.9–11 However, because DXA 
machines are very expensive, not all clinics and hospitals 
are equipped with such devices. Therefore, computed X-ray 
densitometry is usually used in Japanese clinics and hospitals 
that do not have a DXA machine. The efficacy of ALN for 
increasing the lumbar BMD, as determined using DXA, has 
been confirmed in postmenopausal Japanese women with 
osteoporosis.6,7,12,13
The effect of ALN on the BMD of the middle part of the 
metacarpus, which is composed of cortical bone, is poor. 
Tucci et al18 reported the differential effects of ALN on the 
BMD at various skeletal sites. Their results suggested that 
appendicular bones may be less responsive to ALN than 
axial bones in postmenopausal women with osteoporosis; 
distal sites of appendicular bones may be less responsive than 
proximal sites; and smaller appendicular bones may be less 
responsive than larger appendicular bones. Second, the ratio 
of cancellous to cortical bone differs among skeletal sites. 
The lumbar spine is very rich in cancellous bone, whereas 





ALN ALF ALN vs ALF
serum calcium 0.0001 ns ns
serum phosphorus ns ns ns
serum ALP 0.0001 ns 0.0199
Urinary nTX 0.0001 ns 0.0001
Metacarpal BMD ns 0.0026 0.0011
Notes: P values are presented.   The significance of longitudinal changes in biochemical 
markers and metacarpal BMD in the ALn or ALF group was determined using a 
one-way AnOVA with repeated measurements. Differences in longitudinal changes 
in biochemical markers and metacarpal BMD were compared using a 2-way AnOVA 
with repeated measurements.
Abbreviations: AnOVA, analysis of variance; ALn, alendronate; ALF, alfacalcidol; 
BMD, bone mineral density;   ALP, alkaline phosphatase; nTX, cross linked n-terminal 
telopeptides of type I collagen; NS, not significant.Therapeutics and Clinical Risk Management 2009:5 778
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the middle portion of the metacarpus consists of cortical 
bone. Because the acceleration of bone remodeling is widely 
observed on the trabecular surface rather than the endocorti-
cal and intracortical Haversian canal surfaces, cancellous 
bone may be more responsive to ALN than cortical bone. 
However, the results of the present study did not suggest that 
prolonged treatment resulted in any loss of benefit regarding 
metacarpal BMD.
Shiraki et al19 reported that 6 months of treatment with 
ALF reduced the serum levels of parathyroid hormone and 
bone turnover markers in elderly Japanese women with high 
bone turnover osteoporosis. They also reported that treatment 
with ALF for 5 years increased the BMD (+6%) of the radius 
(peripheral cortical bone site) in Japanese patients with 
osteoporosis.20 Orimo et al5 showed that treatment with ALF 
for one year slightly increased the lumbar BMD (+0.65%) 
and reduced the incidence of vertebral fractures in postmeno-
pausal Japanese women with osteoporosis. These results sug-
gest that ALF may reduce bone turnover, increase the BMD, 
and prevent vertebral fractures in postmenopausal Japanese 
women with osteoporosis. In the present study, however, 
long-term treatment with ALF did not affect the urinary NTX 
and serum ALP levels or the metacarpal BMD. The reason 
for this discrepancy between the results of previous studies 
and the present results remains uncertain, although the small 
number of study subjects in the present study might be an 
important factor. Nevertheless, the metacarpal BMD seems 
to have been sustained during the first 18 months after the 
start of ALF treatment (Figure 2). Thus, the short-term effect 
of ALF on BMD might be satisfactory. In addition, the BMD 
of the radius may be more responsive to ALF than that of 
the metacarpus.
The most notable limitation of the present study is its 
retrospective and head-to-head design with a small sample size 
only in postmenopausal Japanese women with an increased 
risk for fractures. First, some of the results, especially those of 
the ALF group, might be biased and the evidence level of our 
results is low. Second, the results might only be applicable for 
postmenopausal Japanese women with an increased risk for 
fractures who consult Japanese general practitioners. Third, 
the safety of ALN, including its side effects, remains uncertain, 
although the safety of treatment with ALN for 10 years has 
been established in postmenopausal Western women with 
osteoporosis.8 Fourth, there was not sufficient statistical power 
to allow a conclusion to be made regarding the effect of ALN 













Figure 2 Changes in metacarpal BMD.
Notes: Data are expressed as the mean ± 95% confidence interval (CI).   The results of statistical analyses are shown in Table 2.
Abbreviations: ALn, alendronate;   ALF, alfacalcidol; BMD, bone mineral density.Therapeutics and Clinical Risk Management 2009:5
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head-to-head trial with a sufficient number of subjects is 
needed to confirm the results of the present study.
In conclusion, the present retrospective study, which was 
performed by Japanese general practitioners, reported the 
outcome of treatment with ALN for 5 years in postmeno-
pausal women with osteoporosis or osteopenia and clinical 
risk factors for fractures. ALN successfully suppressed bone 
turnover and sustained the metacarpal BMD for 5 years in 
postmenopausal Japanese women with an increased risk of 
fractures.
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